Cargando…
Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502
BACKGROUND: While adjuvant chemotherapy is preferable for high-risk colon cancer, treatment duration is controversial. Oral uracil and tegafur (UFT)/leucovorin (LV) is widely used as a standard adjuvant chemotherapy for colon cancer in Japan. We conducted a phase III trial to investigate the optimal...
Autores principales: | Sadahiro, S., Tsuchiya, T., Sasaki, K., Kondo, K., Katsumata, K., Nishimura, G., Kakeji, Y., Baba, H., Sato, S., Koda, K., Yamaguchi, Y., Morita, T., Matsuoka, J., Usuki, H., Hamada, C., Kodaira, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621030/ https://www.ncbi.nlm.nih.gov/pubmed/26347106 http://dx.doi.org/10.1093/annonc/mdv358 |
Ejemplares similares
-
Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial
por: Tsuchiya, Takashi, et al.
Publicado: (2014) -
Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)
por: Sadahiro, Sotaro, et al.
Publicado: (2022) -
Administration Method of Adjuvant Tegafur‐Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study
por: Hata, Taishi, et al.
Publicado: (2021) -
Cost-effectiveness of adjuvant chemotherapy with uracil–tegafur for curatively resected stage III rectal cancer
por: Hisashige, A, et al.
Publicado: (2008) -
S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial
por: Watanabe, J., et al.
Publicado: (2021)